|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> Itacitinib>> 市场分析报告 |
Itacitinib市场分析报告 |
|
Cytokine Release Syndrome – Pipeline Insight, 2020 ... (CRS) related to Covid-19 pneumonia. Itacitinib: Incyte Corporation Itacitinib is a potent, selective JAK1 inhibitor ... LLC Novartis Pharmaceuticals Key Products Itacitinib Dapansutrile Canakinumab Ruxolitinib Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2021 ... -host disease Emerging Drugs Itacitinib: Incyte Corporation Incytes’ novel ... drug candidate, Itacitinib, is an orally administered small molecule in development ... Biotech Pfizer Key Products Itacitinib Glassia MC0518 Inolimomab Etanercept Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2018 Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2018 SUMMARY According to the recently published report 'Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2018'; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or ... Bronchitis– Pipeline Insight, 2020 ... Cysteamine MK-0476 levofloxacin ION-827359 Itacitinib GSK573719 Emeramide DW1601 CKD-497 ... Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018 Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018 SUMMARY Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. The latest report Tyrosine ... Acute Graft-versus-Host Disease - Pipeline Insight, 2021 ... Letolizumab Vedolizumab RGI-2001 Neihulizumab Itacitinib + Tocilizumab TQ05105 CBD Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) ... Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Drugs In Development, 2022, ... Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034 The 7 major Graft vs Host Disease markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6.2 Billion by 2034, exhibiting a growth rate (CAGR) of 14.6% during 2024-2034. The Graft vs Host Disease Market ... |